Ifaz T Haider1,2, Narina Simonian3,4, Amanpreet S Saini3, Frances M Leung3, W Brent Edwards1,2, Thomas J Schnitzer5. 1. Human Performance Laboratory, Faculty of Kinesiology, University of Calgary, Calgary, AB, T2N 1N4, Canada. 2. McCaig Institute for Bone and Joint Health, University of Calgary, Calgary, AB, T2N 1N4, Canada. 3. Department of Physical Medicine and Rehabilitation, Northwestern University Feinberg School of Medicine, Chicago, IL, 60611, USA. 4. Northwestern University Clinical and Translational Sciences Institute, Northwestern University Feinberg School of Medicine, Chicago, IL, 60611, USA. 5. Department of Physical Medicine and Rehabilitation, Northwestern University Feinberg School of Medicine, Chicago, IL, 60611, USA. tjs@northwestern.edu.
Abstract
STUDY DESIGN: Non-randomized open-label clinical trial of oral alendronate after teriparatide therapy in people with spinal cord injury (SCI) and low bone mineral density (BMD). OBJECTIVES: To determine if alendronate would prevent bone loss after discontinuation of teriparatide. SETTING: Outpatient research clinic at Northwestern University Feinberg School of Medicine. METHODS: Seventeen participants with chronic SCI who recently completed 12-24 months of teriparatide treatment received oral alendronate 70 mg once weekly for 12 months. Participants were evaluated at baseline, 6 months and 12 months. Bone was assessed by: DXA at the spine and hip, CT at the distal femur/proximal tibia, serum collected for bone markers, and bone strength determined by finite element (FE) analysis of the proximal tibia. RESULTS: Areal BMD showed no significant change from baseline at the total hip or femoral neck, where mean change (SD) was 1.3% (4.7) and 0.54% (5.0), respectively. However, areal BMD increased significantly at the spine by 2.5% (4.6). CT demonstrated significant increases in bone mineral content at the femoral epiphysis, metaphysis, and diaphysis, 15% (18), 7.7% (12), and 3.0% (3.5), respectively. Measurements at the tibia illustrated improvements and reductions, but no changes to FE-predicted strength were observed. Biomarkers illustrated inhibition of bone formation and resorption, with P1NP and CTX decreasing by 52% (82) and 62% (74), respectively. CONCLUSION: Twelve months of alendronate after discontinuation of teriparatide in people with SCI can prevent bone loss and may increase bone mass and preserve bone strength at the spine, hip, and some sites of the knee.
STUDY DESIGN: Non-randomized open-label clinical trial of oral alendronate after teriparatide therapy in people with spinal cord injury (SCI) and low bone mineral density (BMD). OBJECTIVES: To determine if alendronate would prevent bone loss after discontinuation of teriparatide. SETTING:Outpatient research clinic at Northwestern University Feinberg School of Medicine. METHODS: Seventeen participants with chronic SCI who recently completed 12-24 months of teriparatide treatment received oral alendronate 70 mg once weekly for 12 months. Participants were evaluated at baseline, 6 months and 12 months. Bone was assessed by: DXA at the spine and hip, CT at the distal femur/proximal tibia, serum collected for bone markers, and bone strength determined by finite element (FE) analysis of the proximal tibia. RESULTS: Areal BMD showed no significant change from baseline at the total hip or femoral neck, where mean change (SD) was 1.3% (4.7) and 0.54% (5.0), respectively. However, areal BMD increased significantly at the spine by 2.5% (4.6). CT demonstrated significant increases in bone mineral content at the femoral epiphysis, metaphysis, and diaphysis, 15% (18), 7.7% (12), and 3.0% (3.5), respectively. Measurements at the tibia illustrated improvements and reductions, but no changes to FE-predicted strength were observed. Biomarkers illustrated inhibition of bone formation and resorption, with P1NP and CTX decreasing by 52% (82) and 62% (74), respectively. CONCLUSION: Twelve months of alendronate after discontinuation of teriparatide in people with SCI can prevent bone loss and may increase bone mass and preserve bone strength at the spine, hip, and some sites of the knee.
Authors: R M Neer; C D Arnaud; J R Zanchetta; R Prince; G A Gaich; J Y Reginster; A B Hodsman; E F Eriksen; S Ish-Shalom; H K Genant; O Wang; B H Mitlak Journal: N Engl J Med Date: 2001-05-10 Impact factor: 91.245
Authors: L R Morse; R A Battaglino; K L Stolzmann; L D Hallett; A Waddimba; D Gagnon; A A Lazzari; E Garshick Journal: Osteoporos Int Date: 2008-06-26 Impact factor: 4.507
Authors: Dennis M Black; Susan L Greenspan; Kristine E Ensrud; Lisa Palermo; Joan A McGowan; Thomas F Lang; Patrick Garnero; Mary L Bouxsein; John P Bilezikian; Clifford J Rosen Journal: N Engl J Med Date: 2003-09-20 Impact factor: 91.245
Authors: Y Dionyssiotis; G Trovas; A Galanos; P Raptou; N Papaioannou; P Papagelopoulos; K Petropoulou; G P Lyritis Journal: J Musculoskelet Neuronal Interact Date: 2007 Jan-Mar Impact factor: 2.041
Authors: Michael Kleerekoper; Susan L Greenspan; E Michael Lewiecki; Paul D Miller; David L Kendler; Michael Maricic; Tony M Keaveny; David L Kopperdahl; Valerie A Ruff; Xiaohai Wan; Boris Janos; Kelly Krohn Journal: J Bone Joint Surg Am Date: 2014-06-04 Impact factor: 5.284